According to a recent LinkedIn post from Click Therapeutics Inc, the company is emphasizing the strategic role of Prescription Drug Use-Related Software (PDURS) as a tool to enhance pharmaceutical brands beyond traditional drug development. The post references a collaborative piece with IQVIA that argues PDURS can bridge digital innovation and commercial outcomes across the life sciences sector.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post highlights industry headwinds, including a roughly steady rate of about 50 U.S. drug approvals per year and a projected $300 billion revenue impact by 2030 as patents expire. It suggests that payers’ rising demands for clinical and economic value may increase interest in software-enhanced therapies that can be integrated into FDA-authorized drug labels.
According to the post, Software-Enhanced Drugs™ may allow pharmaceutical companies to improve patient outcomes, differentiate efficacy beyond pharmacotherapy alone, and defend market share past loss of exclusivity through software-as-a-medical-device (SaMD) intellectual property. Click Therapeutics is presented as positioning its digital therapeutics to meet regulatory and evidentiary requirements aligned with PDURS standards.
For investors, the post implies that Click Therapeutics is targeting a role as an enabling partner for pharma seeking digital adjuncts to existing therapies. If PDURS adoption grows and payers recognize software-driven benefits, this strategy could support long-term revenue opportunities via co-developed products, licensing, or SaaS-like models, while also embedding the company deeper into large pharma commercialization workflows.